Addressing systemic barriers and implementing policies can reduce disparities in healthcare access and promote equity in treatment. Increasing awareness and education among healthcare providers ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...

Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Treatments for localised prostate cancer have long been aimed at treating the whole prostate, either by surgical removal or by radiotherapy. However ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...